Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.74 - venombin A

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abscess
Effect of systemic fibrinogen depletion on intraabdominal abscess formation.
Activated Protein C Resistance
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
The effects of transport temperature and time on routine and specialized coagulation assays.
Acute Lung Injury
Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury.
Adenocarcinoma
Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors.
Metalloproteinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in endometrial flushings from pre- and post-menopausal women and from women with endometrial adenocarcinoma.
Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
Afibrinogenemia
Fibrin deposition in the central nervous system correlates with the degree of Theiler's murine encephalomyelitis virus-induced demyelinating disease.
Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injury.
Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats.
Alveolar Bone Loss
Exenatide and Sitagliptin Decrease Interleukin 1?, Matrix Metalloproteinase 9, and Nitric Oxide Synthase 2 Gene Expression But Does Not Reduce Alveolar Bone Loss in Rats With Periodontitis.
Amyloidosis
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Aneurysm
Apolipoprotein E Knockout Mice Over-Expressing Human Tissue Inhibitor of Metalloproteinase 1 Are Protected against Aneurysm Formation but Not against Atherosclerotic Plaque Development.
Angina, Unstable
Enoxaparin for unstable angina and ancrod for cardiac surgery following heparin allergy.
Aortic Aneurysm
Correlation of bacterial coinfection versus matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 expression in aortic aneurysm and atherosclerosis.
Aortic Aneurysm, Abdominal
Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease.
Appendicitis
Local and systemic expressions of MMP-9, TIMP-1 and PAI-1 in patients undergoing surgery for clinically suspected appendicitis.
Arterial Occlusive Diseases
Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia.
[Defibrination with ancrod (arvin) in peripheral arterial occlusive diseases. Principle, indications, contraindications technic and course]
[Results of treatment with ancrod (Arwin) in 21 patients with chronic arterial occlusive disease]
[Thrombotic arterial and venous obstructions under ancrod (Arwin) therapy (author's transl)]
Arthritis
Clumping factor A-mediated virulence during Staphylococcus aureus infection is retained despite fibrinogen depletion.
Arthritis, Infectious
Clumping factor A-mediated virulence during Staphylococcus aureus infection is retained despite fibrinogen depletion.
Arthritis, Psoriatic
Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.
Arthritis, Rheumatoid
Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts.
Discovery and analysis of inflammatory disease-related genes using cDNA microarrays.
Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression.
Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts.
The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.
Asthma
Effect of montelukast on markers of airway remodeling in children with asthma.
IL-17 Is a Key Regulator of Mucin-Galectin-3 Interactions in Asthma.
Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma.
Remodeling associated expression of matrix metalloproteinase 9 but not tissue inhibitor of metalloproteinase 1 in airway epithelium: Modulation by immunostimulatory DNA.
Atherosclerosis
Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study.
Correlation of bacterial coinfection versus matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 expression in aortic aneurysm and atherosclerosis.
[The effect of batroxobin on atherosclerosis]
Atrial Fibrillation
Effect of batroxobin on spontaneous echo contrast and hemorheology in left atrial appendage in atrial fibrillation assessed by transesophageal echocardiograpy.
Bernard-Soulier Syndrome
Purification and characterization of bothrombin, a fibrinogen-clotting serine protease from the venom of Bothrops jararaca.
Biliary Atresia
Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver.
Brain Edema
Effects of venom defibrase on brain edema after intracerebral hemorrhage in rats.
[Neuroprotective effect of batroxobin on experimental intracerebral hemorrhage in rats]
Brain Infarction
Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators.
Brain Injuries
Effect of batroxobin on neuronal apoptosis during focal cerebral ischemia and reperfusion in rats.
Protective effects of batroxobin on a nigrostriatal pathway injury in mice.
Brain Ischemia
Ancrod reduces intracerebral hemorrhage quantified in vivo by magnetic resonance imaging in rats.
Effect of batroxobin on neuronal apoptosis during focal cerebral ischemia and reperfusion in rats.
The neuroprotective effect of MicroRNA-149-5p and coenzymeQ10 by reducing levels of inflammatory cytokines and metalloproteinases following focal brain ischemia in rats.
Breast Neoplasms
Matrix Metalloproteinase-9 as a Potential Tumor Marker in Breast Cancer.
Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1.
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Roles of the cyclooxygenase 2-matrix metalloproteinase 1 pathway in brain metastasis of breast cancer.
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Burkitt Lymphoma
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Carcinogenesis
Activation of Epidermal Growth Factor Receptor/p38/Hypoxia-inducible Factor-1? Is Pivotal for Angiogenesis and Tumorigenesis of Malignantly Transformed Cells Induced by Hexavalent Chromium.
Identification of genes associated with progression and metastasis of advanced cervical cancers after radiotherapy by cDNA microarray analysis.
Tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic biomarker in gastrointestinal cancer: a meta-analysis.
Carcinoma
Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.
Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems.
Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines.
Growth and metastasis of the Lewis lung carcinoma in mice defibrinated with batroxobin.
Interstitial collagenase (matrix metalloproteinase 1) associated with the plasma membrane of both neoplastic and nonneoplastic cells.
Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia.
Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of recurrent respiratory papillomatosis and for prognosis of laryngeal cancer.
Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
[A preliminary clinical study on the treatment of primary hepatic carcinoma by transcatheter arterial perfusion of batroxobin combined with TACE]
[Detection of fibrinolytic split products in patient collections with disordered hemostasis. I. In pathologically verified lung cancer. II. In thrombotic/embolic occurrences]
Carcinoma, Ehrlich Tumor
The effect of cycloheximide, heparin and ancrod on mice given Ehrlich ascites tumour cells intravenously.
Carcinoma, Hepatocellular
Reptilase test in cirrhosis and hepatocellular carcinoma.
Reptilase time in cirrhosis and hepatocellular carcinoma.
Carcinoma, Lewis Lung
Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems.
Growth and metastasis of the Lewis lung carcinoma in mice defibrinated with batroxobin.
Carcinoma, Renal Cell
Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.
Cerebral Hemorrhage
Ancrod reduces intracerebral hemorrhage quantified in vivo by magnetic resonance imaging in rats.
Effects of venom defibrase on brain edema after intracerebral hemorrhage in rats.
[Neuroprotective effect of batroxobin on experimental intracerebral hemorrhage in rats]
Cerebral Infarction
Metabolic changes in rats with photochemically induced cerebral infarction and the effects of batroxobin: a study by magnetic resonance imaging, 1H- and 31P-magnetic resonance spectroscopy.
Use of ancrod in acute or progressing ischemic cerebral infarction.
[Effectiveness of urokinase used in combination with batroxobin (DF-521) in rat model of focal cerebral ischemia-reperfusion]
Chemical and Drug Induced Liver Injury
Serum markers of liver fibrogenesis, and liver histology findings in patients with chronic liver diseases.
Cholangitis, Sclerosing
Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver.
Chorioamnionitis
Amniotic fluid concentrations of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during pregnancy and labor.
coagulation factor xa deficiency
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Coinfection
Correlation of bacterial coinfection versus matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 expression in aortic aneurysm and atherosclerosis.
Colonic Neoplasms
Comparative quantitation of aberrant glycoforms by lectin-based glycoprotein enrichment coupled with multiple-reaction monitoring mass spectrometry.
Colorectal Neoplasms
Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases.
Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases.
Evaluation of an improved tissue inhibitor of metalloproteinase 1 dual monoclonal sandwich immunoassay.
Identification of low-abundance cancer biomarker candidate TIMP1 from serum with lectin fractionation and peptide affinity enrichment by ultrahigh-resolution mass spectrometry.
Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry.
Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: associations with clinicopathological variables and patient survival.
Corneal Neovascularization
Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization.
Coronary Stenosis
Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries.
[The effect of batroxobin on coronary segmental resistance and coronary blood flow in acute myocardial ischemic dogs]
Coronary Thrombosis
Ancrod decreases the frequency of cyclic flow variations and causes thrombolysis following acute coronary thrombosis.
Preventive effects of batroxobin on experimental canine coronary thrombosis.
Cystic Fibrosis
Identification of genes and pathways in esophageal adenocarcinoma using bioinformatics analysis.
Demyelinating Diseases
Characterization of astrocyte plasminogen activator.
Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis.
Fibrinogen Depleting Agent Batroxobin has a Beneficial Effect on Experimental Autoimmune Encephalomyelitis.
Dermatomyositis
Serum concentrations of carboxyterminal propeptide of type 1 procollogen and tissue inhibitor of metalloproteinase 1 in patients with dermatomyositis.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation induced by liquoid in the rat. IV. Modification of the generalized Shwartzman reaction by ancrod and cobra venom factor.
Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC).
The effects of defibrinogenation with batroxobin on endotoxin-induced disseminated intravascular coagulation in rats.
The influence of drugs on disseminated intravascular coagulation (DIC). IV. Effects on the thrombin-like enzyme batroxobin on thrombin-induced DIC in rats.
[Coagulation factors and thrombocytes after application of Reptilase in the course of gynecologic operations (author's transl)]
[Diagnostic therapeutic problems of defibrination syndrome in shock, sepsis, and neonatal hypoxia (author's transl)]
[Recommendations for initial diagnosis and therapy in acute blood coagulation disorders]
Down Syndrome
Acquired coagulation inhibitor delaying fibrinopeptide release.
Encephalomyelitis
Fibrinogen Depleting Agent Batroxobin has a Beneficial Effect on Experimental Autoimmune Encephalomyelitis.
Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats.
Encephalomyelitis, Autoimmune, Experimental
Characterization of astrocyte plasminogen activator.
Fibrinogen Depleting Agent Batroxobin has a Beneficial Effect on Experimental Autoimmune Encephalomyelitis.
Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats.
Endometriosis
Reduced fecundity in female rats with surgically induced endometriosis and in their daughters: a potential role for tissue inhibitors of metalloproteinase 1.
Esophageal Neoplasms
Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients.
Factor X Deficiency
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Fatty Liver
Serum markers of liver fibrogenesis, and liver histology findings in patients with chronic liver diseases.
Fetal Growth Retardation
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Glioblastoma
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Glioma
Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients.
Glomerulonephritis
A comparison of fibrinolytic and defibrinating agents in established experimental glomerulonephritis.
Ancrod improves survival in murine systemic lupus erythematosus.
Ancrod in glomerulonephritis.
Defibrination with ancrod in glomerulonephritis: effects on clinical and histologic findings and on blood coagulation.
Defibrination with ancrod: effect on reticuloendothelial clearance of circulating immune complexes.
Effects of ancrod and rtPA on fibrin accumulation, glomerular inflammation and renal function in nephrotoxic nephritis.
Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats.
Fibrin independent proinflammatory effects of tissue factor in experimental crescentic glomerulonephritis.
Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod.
The effect of defibrination on macrophage participation in rabbit nephrotoxic nephritis: studies using glomerular culture and electronmicroscopy.
Granuloma
The effect of angrod on the delayed hypersensitivity response in rats.
Hearing Loss, Sensorineural
Efficacy of intratympanic corticosteroid, intravenous batroxobin and combined treatment for sudden sensorineural hearing loss with type-2 diabetes.
Hearing Loss, Sudden
Hearing recovery in sudden deafness patients using a modified defibrinogenation therapy.
The effect of batroxobin on cochlear blood flow.
Heart Diseases
Serum and tissue biomarkers in aortic stenosis.
Heart Failure
Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.
Heart Rupture
Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction.
Heart Septal Defects, Ventricular
Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis.
Hemochromatosis
Evidence for altered hepatic matrix degradation in genetic haemochromatosis.
Hemoptysis
Hemoptysis after batroxobin infusion using a fiberoptic bronchoscope.
Paradoxical pulmonary hemorrhage associated with hemocoagulase batroxobin in a patient with hemoptysis: A CARE-compliant case report.
Hemorrhagic Disorders
Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.
[Clinical experiences with reptilase in hemorrhagic diathesis and postoperative hemorrhage]
Hemorrhagic Stroke
Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention.
Hepatitis B
Serum markers of liver fibrogenesis, and liver histology findings in patients with chronic liver diseases.
Hepatitis B, Chronic
[The relationship between TGFbeta1 and TIMP-1 and its effects on the diagnosis of hepatic fibrosis]
Hepatitis, Chronic
Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.
Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis.
Hyperemia
[Multivariate analysis for the understanding of typical diabetic hemostasis criteria. 1: Plasma markers]
Hypersensitivity
Enoxaparin for unstable angina and ancrod for cardiac surgery following heparin allergy.
Hypersensitivity, Delayed
The effect of angrod on the delayed hypersensitivity response in rats.
Hypertension
[Correlation between prognosis and laboratory parameters of complete deafness in patients with sudden deafness?].
Hypoventilation
Effects of hemorrhage, hypoxia, and intravascular coagulation on bacterial clearance and translocation.
Infarction, Middle Cerebral Artery
Magnetic resonance imaging studies on the effect of the fibrinogen-lowering agent ancrod on cerebral lesions in two rat models of acute stroke.
MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats.
Infections
Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions.
Tissue inhibitor of metalloproteinase 1 regulates resistance to infection.
Urinary matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 biomarkers for predicting renal scar in children with urinary tract infection.
[Inhibition of quercetin on liver fibrosis due to Schistosoma japonicum infection and on the expression of immediate early gene and metalloproteinase 1 inhibitor in liver tissue of mice]
Inflammatory Bowel Diseases
Discovery and analysis of inflammatory disease-related genes using cDNA microarrays.
Intermittent Claudication
Therapeutic defibrinogenation by ancrod: effect on limb blood flow in peripheral vascular disease.
Treatment of severe intermittent claudication by controlled defibrination.
[Time differences between elevation of muscular oxygen tension and increase in painfree walking distance during treatment of severe intermittent claudication with ancrod]
Intervertebral Disc Degeneration
Effects of Transplantation of hTIMP1-Expressing Bone Marrow Mesenchymal Stem Cells on the Extracellular Matrix of Degenerative Intervertebral Discs in an in vivo Rabbit Model.
Lentivirus-mediated TGF-?3, CTGF and TIMP1 gene transduction as a gene therapy for intervertebral disc degeneration in an in vivo rabbit model.
[Effect of Acupotomy Lysis at Cervical Acupoints on Expression of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinase 1 and Changes of Pulpiform Nucleus Ultrastructure in Rats with Degenerated Cervical Intervertebral Discs].
Intracranial Hemorrhages
Ancrod in Acute Ischemic Stroke. Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program.
Effects of Batroxobin with Continuous Transcranial Doppler Monitoring in Patients with Acute Cerebral Stroke: A Randomized Controlled Trial.
Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial.
The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis.
[Effectiveness of urokinase used in combination with batroxobin (DF-521) in rat model of focal cerebral ischemia-reperfusion]
Intracranial Thrombosis
Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization.
Ischemic Stroke
Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
Ancrod and Fibrin Formation: Perspectives on Mechanisms of Action.
Ancrod for acute ischemic stroke: a new dosing regimen derived from analysis of prior ancrod stroke studies.
Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators.
Ancrod in Acute Ischemic Stroke. Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program.
Ancrod in the treatment of acute ischaemic stroke.
Ancrod in the treatment of acute ischemic stroke. A review of clinical data.
Clinical experience with Ancrod in acute ischaemic stroke.
Controlled trial of ancrod in ischemic stroke.
Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT).
Deep Vein Thrombosis After Total Hip Arthroplasty and Total Knee Arthroplasty in Patients With Previous Ischemic Stroke.
Experimental ancrod (Arvin) for acute ischemic stroke: nursing implications.
Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial.
Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial.
Outcomes of ancrod in acute ischemic stroke
Outcomes of ancrod in acute ischemic stroke.
Outcomes of ancrod in acute ischemic stroke. Independent Data and Safety Monitoring Board for ESTAT. Steering Committee for ESTAT. European Stroke Treatment with Ancrod Trial.
PEGylation: a successful approach to improve the biopharmaceutical potential of snake venom thrombin-like serine protease.
Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod.
Stroke trials: what have we learned?
[Batroxobin in patients with ischemic stroke in the carotid system (the multicenter study)]
Kidney Cortex Necrosis
Further analysis of lethal factors in cycloheximide-treated mice given low doses of bacterial lipopolysaccharide.
Kidney Failure, Chronic
Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod.
Kidney Neoplasms
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Laryngeal Neoplasms
Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of recurrent respiratory papillomatosis and for prognosis of laryngeal cancer.
Leprosy, Tuberculoid
Schwann cells producing matrix metalloproteinases under Mycobacterium leprae stimulation may play a role in the outcome of leprous neuropathy.
Leukemia
Freshly isolated osteoarthritic chondrocytes are catabolically more active than normal chondrocytes, but less responsive to catabolic stimulation with interleukin-1beta.
Leukemia, Myeloid, Acute
Reptilase for ANLL with DIC.
Liver Cirrhosis
Antifibrotic Effects of a Recombinant Adeno-Associated Virus Carrying Small Interfering RNA Targeting TIMP-1 in Rat Liver Fibrosis.
Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice.
Diagnosing schistosomiasis-induced liver morbidity: implications for global control.
Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats.
Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects.
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.
Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
Suppression by fucoidan of liver fibrogenesis via the TGF-?/Smad pathway in protecting against oxidative stress.
Transplantation of mesenchymal stem cells expressing TIMP-1-shRNA improves hepatic fibrosis in CCl?-treated rats.
[Inhibition of quercetin on liver fibrosis due to Schistosoma japonicum infection and on the expression of immediate early gene and metalloproteinase 1 inhibitor in liver tissue of mice]
[Possibility of Using ELF Score as Index for Hepatic Fibrosis Evaluation].
[The relationship between TGFbeta1 and TIMP-1 and its effects on the diagnosis of hepatic fibrosis]
Liver Cirrhosis, Biliary
Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver.
Serum markers of liver fibrogenesis, and liver histology findings in patients with chronic liver diseases.
Liver Diseases
Acquired dysfibrinogenaemia in acute and chronic liver disease.
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Liver Neoplasms
Expression, purification and characterization of a novel recombinant SVTLE, r-agkihpin-2, from Gloydius halys Pallas venom gland in Escherichia coli.
Lung Neoplasms
[Expressions of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 and their correlation with metastasis and prognosis in lung cancer.]
Lupus Erythematosus, Systemic
Ancrod improves survival in murine systemic lupus erythematosus.
Ancrod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolysis effects.
Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod.
Lupus Nephritis
Ancrod improves survival in murine systemic lupus erythematosus.
Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
Deficiency of a plasma factor stimulating vascular prostacyclin generation in patients with lupus nephritis and glomerular thrombi and its correction by ancrod: in-vivo and in-vitro observations.
Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod.
Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod.
Lymphoma
[Anti-sense miRNA-21 oligonucleotide inhibits Tb 3.1 human tongue squamous cell carcinoma growth in vitro.]
Lymphoma, B-Cell
Effects of tetrahedral framework nucleic acid/wogonin complexes on osteoarthritis.
[Anti-sense miRNA-21 oligonucleotide inhibits Tb 3.1 human tongue squamous cell carcinoma growth in vitro.]
Malaria
Ancrod, heparin, and -aminocaproic acid in simian Knowlesi malaria.
Massive Hepatic Necrosis
Effect of plasma exchange on serum tissue inhibitor of metalloproteinase 1 and cytokine concentrations in patients with fulminant hepatitis.
Melanoma
Serum markers in early-stage and locally advanced melanoma.
[The inhibitory effect of batroxobin against the lung metastasis of the B16-F10 melanoma cells implanted in the mice in relation to the activity of the NK cell]
Melanoma, Experimental
Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems.
Antitumor action of crotalase, a defibrinogenating snake venom enzyme.
[Role of natural killer cells in the antimetastatic effect of defibrinogenation with batroxobin]
Memory Disorders
Effect of batroxobin on expression of c-Jun in left temporal ischemic rats with spatial learning and memory disorder.
Effect of batroxobin on expression of neural cell adhesion molecule in temporal infarction rats and spatial learning and memory disorder.
Effects of batroxobin on spatial learning and memory disorder of rats with temporal ischemia and the expression of HSP32 and HSP70.
Menorrhagia
Defective fibrinogen polymerization associated with a novel gamma279Ala-->Asp mutation.
Movement Disorders
[Batroxobin in patients with ischemic stroke in the carotid system (the multicenter study)]
Mucocutaneous Lymph Node Syndrome
Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease.
Multiple Sclerosis
Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis.
Myocardial Infarction
Agkistrodon acutus-purified protein C activator protects human umbilical vein endothelial cells against H2O2-induced apoptosis.
Defibrinogenating enzymes.
PEGylation: a successful approach to improve the biopharmaceutical potential of snake venom thrombin-like serine protease.
Myocardial Ischemia
[The effect of batroxobin on coronary segmental resistance and coronary blood flow in acute myocardial ischemic dogs]
Myocardial Stunning
Decreased expression of tissue inhibitor of metalloproteinase 1 in stunned myocardium.
Nasal Polyps
Expression of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 1 in nonrecurrent vs recurrent nasal polyps.
Neoplasm Metastasis
Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.
Antimetastatic effect of defibrinogenation with batroxobin depends on the natural killer activity of host in mice.
Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases.
Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice.
Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases.
Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients.
Evaluation on biological compatibility of carboxymethyl chitosan as biomaterials for antitumor drug delivery.
Growth and metastasis of the Lewis lung carcinoma in mice defibrinated with batroxobin.
Identification of genes associated with progression and metastasis of advanced cervical cancers after radiotherapy by cDNA microarray analysis.
Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice.
Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.
Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo.
Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin.
Roles of the cyclooxygenase 2-matrix metalloproteinase 1 pathway in brain metastasis of breast cancer.
Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumour metastasis.
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
[Expressions of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 and their correlation with metastasis and prognosis in lung cancer.]
[Role of natural killer cells in the antimetastatic effect of defibrinogenation with batroxobin]
[The inhibitory effect of batroxobin against the lung metastasis of the B16-F10 melanoma cells implanted in the mice in relation to the activity of the NK cell]
Neoplasms
A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen.
Aberrant histone modification and inflammatory cytokine production of peripheral CD4+ T cells in patients with oral lichen planus.
Analysis of Gene Expression in Experimental Pressure Ulcers in the Rat with Special Reference to Inflammatory Cytokines.
Antitumor action of crotalase, a defibrinogenating snake venom enzyme.
Balance of Profibrotic and Antifibroting Signaling in Nephrogenic Systemic Fibrosis Skin Lesions.
Batroxobin accelerated tissue repair via neutrophil extracellular trap regulation and defibrinogenation in a murine ischemic hindlimb model.
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?
Carboxymethyl chitosan represses tumor angiogenesis in vitro and in vivo.
Colorectal cancer detection by biomarker quantification in noninvasively collected colorectal mucus: preliminary comparison of 24 protein biomarkers.
Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects.
Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines.
Differential Protein Expression Profiles in Glaucomatous Trabecular Meshwork: An Evaluation Study on a Small Primary Open Angle Glaucoma Population.
Do aberrant crypt foci have predictive value for the occurrence of colorectal tumours? Potential of gene expression profiling in tumours.
Down-regulation of expression of osteoblast and osteocyte markers in periodontal tissues associated with the spontaneous alveolar bone loss of interleukin-10 knockout mice.
Effect of defibrination on tumor growth and response to chemotherapy.
Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients.
Evaluation of the Activity of Heparin Injected into the Fully Implantable Catheter for Chemotherapy (Portocath) between Two Moments of Use.
Evaluation on biological compatibility of carboxymethyl chitosan as biomaterials for antitumor drug delivery.
Extracellular vesicles participate in the transport of cytokines and angiogenic factors in diabetic patients with ocular complications.
Gender in cardiac resynchronisation therapy.
Hepatoprotective effect of a fucoidan extract from Sargassum fluitans Borgesen against CCl4-induced toxicity in rats.
Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Hydrostatic pressure induces expression of interleukin 6 and tumour necrosis factor alpha mRNAs in a chondrocyte-like cell line.
Immunopathologic characteristics of nasal polyps in adult Koreans: A single-center study.
Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1.
Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.
Liver acid sphingomyelinase inhibits growth of metastatic colon cancer.
Matrix Metalloproteinase-9 as a Potential Tumor Marker in Breast Cancer.
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Mifepristone alleviates cerebral ischemia-reperfusion injury in rats by stimulating PPAR ?.
Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma.
Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.
Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis.
Preference of Aerosolized Pirfenidone to Oral Intake: An Experimental Model of Pulmonary Fibrosis by Paraquat.
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry.
Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin.
Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model.
Schwann cells producing matrix metalloproteinases under Mycobacterium leprae stimulation may play a role in the outcome of leprous neuropathy.
Serum and tissue biomarkers in aortic stenosis.
Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell.
Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumour metastasis.
Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer.
TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.
The activation of TLR7 regulates the expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells.
The effect of cycloheximide, heparin and ancrod on mice given Ehrlich ascites tumour cells intravenously.
The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells.
The therapeutic effect of aucubin-supplemented hyaluronic acid on interleukin-1beta-stimulated human articular chondrocytes.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer.
Tumor necrosis factor receptor deficiency alters matrix metalloproteinase 13/tissue inhibitor of metalloproteinase 1 expression in murine silicosis.
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38?, and NF-?B signaling.
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
[Effect of hydrocinnamoyl-L-valyl pyrrolidine on healing quality of deep partial-thickness scald wound in mice].
Neoplastic Cells, Circulating
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Nephritis
A quantitative evaluation of anticoagulants in experimental nephrotoxic nephritis.
Comparative effects of heparin, urokinase, and ancrod on intraglomerular coagulation induced in progressive Masugi nephritis.
Defibrination with ancrod in nephrotoxic nephritis in rabbits.
Effects of ancrod and rtPA on fibrin accumulation, glomerular inflammation and renal function in nephrotoxic nephritis.
The effect of hypofibrinogenemia with batroxobin on rat Masugi nephritis.
[Comparative effects of ancrod, urokinase and heparin on intraglomerular coagulation induced by progressive Masugi nephritis (author's transl)]
Nephrosis
The prolonged thrombin time of nephrotic syndrome.
Neuralgia
Comparison of gene expression profiles in neuropathic and inflammatory pain.
Neurofibromatosis 1
Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.
Neuroinflammatory Diseases
Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease.
Neutropenia
The role of granulocytes in the activation of intravascular coagulation and the precipitation of soluble fibrin by endotoxin.
Non-alcoholic Fatty Liver Disease
Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Obstetric Labor, Premature
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Otitis Media with Effusion
[Relationship between the content of fibrinogen in middle ear effusion and the effect of treatment on secretory otitis media]
Ovarian Neoplasms
Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.
Pancreatic Neoplasms
Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach.
Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study.
Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
Pancreatitis
Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach.
The imbalance between matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in acute pancreatitis.
Papilloma
Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of recurrent respiratory papillomatosis and for prognosis of laryngeal cancer.
Paraproteinemias
[Increased thrombin time in a patient with multiple myeloma]
Peripheral Arterial Disease
Subcutaneous ancrod therapy in peripheral arterial disease: improvement in blood viscosity and nutritional blood flow.
Peripheral Vascular Diseases
The effect of ancrod on perfusion of myocutaneous flaps.
The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
Therapeutic defibrinogenation by ancrod: effect on limb blood flow in peripheral vascular disease.
Use of ancrod in acute or progressing ischemic cerebral infarction.
Pleural Effusion
[The establishment of a guinea pig model of inflammatory pleural effusion and the effect of batroxobin in the prevention of pleural encapsulation]
Pneumonia
IL-17 Is a Key Regulator of Mucin-Galectin-3 Interactions in Asthma.
Polycystic Kidney Diseases
A possible role for metalloproteinases in renal cyst development.
Priapism
Defibrinogenating enzymes.
Prostatic Neoplasms
Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.
Pulmonary Disease, Chronic Obstructive
Expressions of TOLL-like receptor 4 (TLR-4) and matrix metalloproteinase 9 (MMP-9)/Tissue inhibitor of metalloproteinase 1 (TIMP-1) in pulmonary blood vessels with chronic obstructive pulmonary diseases and their relationships with pulmonary vascular remodelling.
The correlation of age and body mass index with the level of both protease MMP3 and anti-protease TIMP-1 among Indonesian patients with chronic obstructive pulmonary disease: a preliminary findings.
[The influence of smoking on the metalloproteinase 1 (MMP-1) concentration in serum in the group of patients with chronic obstructive pulmonary disease]
Pulmonary Embolism
Ancrod as prophylaxis or treatment for thromboembolism in patients with multiple trauma.
Pulmonary Fibrosis
Ginsenoside Rg1 Ameliorates Cigarette Smoke-Induced Airway Fibrosis by Suppressing the TGF-?1/Smad Pathway In Vivo and In Vitro.
Purpura Fulminans
[Meningococcal purpura fulminans: treatment with recombinant protein C activator in 3 cases]
Pyelonephritis
Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation.
Urinary matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 biomarkers for predicting renal scar in children with urinary tract infection.
Raynaud Disease
Treatment of patients with secondary Raynaud's syndrome.
Renal Insufficiency
Defibrination with ancrod in nephrotoxic nephritis in rabbits.
Effects of ancrod and rtPA on fibrin accumulation, glomerular inflammation and renal function in nephrotoxic nephritis.
Reperfusion Injury
Influence of batroxobin on cerebral ischemia-reperfusion injury in gerbils.
Therapeutic defibrination with ancrod does not protect canine myocardium from reperfusion injury.
Respiratory Insufficiency
Effect of reptilase on respiratory insufficiency induced by intravenous infusion of thrombin and AMCA (tranexamic acid) in the dog.
Retinal Degeneration
Fine mapping of canine XLPRA establishes homology of the human and canine RP3 intervals.
retinal dehydrogenase deficiency
Retinol dehydrogenase 13 deficiency diminishes carbon tetrachloride-induced liver fibrosis in mice.
Retinal Neovascularization
Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis.
Retinal Vein Occlusion
Treatment of central retinal vein thrombosis with ancrod.
Sarcoidosis
Reduced pulmonary function is associated with enhanced inflammation and tissue inhibitor of metalloproteinase 1 concentration in the bronchoalveolar lavage fluid of patients with lung parenchymal sarcoidosis.
Sarcoma
Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice.
Schistosomiasis japonica
[Inhibition of quercetin on liver fibrosis due to Schistosoma japonicum infection and on the expression of immediate early gene and metalloproteinase 1 inhibitor in liver tissue of mice]
Scoliosis
Which is more effective in adolescent idiopathic scoliosis surgery: batroxobin, tranexamic acid or a combination?
Seizures
Use of ancrod in acute or progressing ischemic cerebral infarction.
Severe Combined Immunodeficiency
Biochemical indicators of implantation success of tissue-engineered oral mucosa.
Shwartzman Phenomenon
Disseminated intravascular coagulation induced by liquoid in the rat. IV. Modification of the generalized Shwartzman reaction by ancrod and cobra venom factor.
Mortality and platelet depletion occur independently of fibrinogen consumption in murine models of tumour necrosis factor-mediated systemic inflammatory responses.
Production of the generalized Shwartzman reaction in rabbits by ancrod ('Arvin') infusion and endotoxin injection.
Silicosis
Tumor necrosis factor receptor deficiency alters matrix metalloproteinase 13/tissue inhibitor of metalloproteinase 1 expression in murine silicosis.
Sinus Thrombosis, Intracranial
The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis.
Spinal Cord Injuries
Batroxobin protects against spinal cord injury in rats by promoting the expression of vascular endothelial growth factor to reduce apoptosis.
Protective effects of Batroxobin on spinal cord injury in rats.
Squamous Cell Carcinoma of Head and Neck
Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of recurrent respiratory papillomatosis and for prognosis of laryngeal cancer.
Stomach Neoplasms
Expression of tissue inhibitors of metalloproteinase 1 (TIMP-1) in gastric cancer tissue.
Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.
Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo.
Stroke
Ancrod and Fibrin Formation: Perspectives on Mechanisms of Action.
Ancrod causes rapid thrombolysis in patients with acute stroke.
Ancrod for acute ischemic stroke: a new dosing regimen derived from analysis of prior ancrod stroke studies.
Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators.
Ancrod in Acute Ischemic Stroke. Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program.
Ancrod reduces intracerebral hemorrhage quantified in vivo by magnetic resonance imaging in rats.
Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis.
Ancrod.
Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT).
Defibrinogenating enzymes.
Development of an ischemic stroke survival score.
Effects of Batroxobin with Continuous Transcranial Doppler Monitoring in Patients with Acute Cerebral Stroke: A Randomized Controlled Trial.
Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention.
Hyperfibrinogenemia and functional outcome from acute ischemic stroke.
Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial.
Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial.
Magnetic resonance imaging studies on the effect of the fibrinogen-lowering agent ancrod on cerebral lesions in two rat models of acute stroke.
MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats.
Outcomes of ancrod in acute ischemic stroke. Independent Data and Safety Monitoring Board for ESTAT. Steering Committee for ESTAT. European Stroke Treatment with Ancrod Trial.
Potential Applications of Venom Peptides as Anti-Thrombotic Agents for Management of Arterial and Deep-Vein Thrombosis.
The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah.
The stroke pharmacopeia: promising experimental therapies.
Thrombolysis.
Use of ancrod in acute or progressing ischemic cerebral infarction.
Subacute Sclerosing Panencephalitis
Response of extracellular matrix regulators in mouse lung after exposure to photons, protons and simulated solar particle event protons.
Temporomandibular Joint Disorders
Expression of collagenases (matrix metalloproteinase-1, 8, 13) and tissue inhibitor of metalloproteinase-1 of retrodiscal tissue in temporomandibular joint disorder patients.
Tendinopathy
Increased expression of matrix metalloproteinase 1 (MMP1) in 11 patients with patellar tendinosis.
Thrombocytopenia
Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis.
Ancrod infusion for anticoagulation during and after PTCA in a patient with heparin-induced thrombocytopenia.
Ancrod: a practical alternative to heparin.
Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management.
Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
Effect of platelet antiserum on the precipitation of soluble fibrin by endotoxin.
Hematin: unique effects of hemostasis.
Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation.
Heparin-associated thrombocytopenia and thrombosis: optimal therapy with ancrod.
Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development.
Normal activated clotting time despite adequate anticoagulation with ancrod in a patient with heparin-associated thrombocytopenia and thrombosis undergoing cardiopulmonary bypass.
Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia.
Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
Systemic haemorrhage in rats induced by a haemorrhagic fraction from Bothrops jararaca venom.
Systemic lupus erythematosus presenting with haemorrhagic manifestation.
The interaction of ancrod with human platelets.
The role of blood platelets in the precipitation of soluble fibrin by endotoxin.
Uses of heparin. Ancrod for heparin induced thrombocytopenia.
Venomics of Calloselasma rhodostoma, the Malayan pit viper: A complex toxin arsenal unraveled.
Thromboembolism
Ancrod as prophylaxis or treatment for thromboembolism in patients with multiple trauma.
Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study.
Use of ancrod in acute or progressing ischemic cerebral infarction.
Use of defibrinating agents ancrod and reptilase in the treatment of thromboembolism.
Thrombophilia
c.259A>C in the fibrinogen gene of alpha chain (FGA) is a fibrinogen with thrombotic phenotype.
Thrombosis
A novel model of occlusive thrombus formation in mice.
Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis.
Ancrod as prophylaxis or treatment for thromboembolism in patients with multiple trauma.
Ancrod decreases the frequency of cyclic flow variations and causes thrombolysis following acute coronary thrombosis.
Ancrod enhances the thrombolytic effect of streptokinase and urokinase.
Ancrod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolysis effects.
Ancrod: a practical alternative to heparin.
Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management.
Antithrombin and thrombolytic effects of a new antithrombin agent: angioscopic and angiographic comparison with heparin or batroxobin.
Application of a monoclonal antibody to estimate rabbit fibrinopeptide A released by habutobin.
Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin.
Batroxobin in combination with anticoagulation may promote venous sinus recanalization in cerebral venous thrombosis: A real-world experience.
Batroxobin Mobilizes Circulating Endothelial Progenitor Cells in Patients With Deep Vein Thrombosis.
Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia.
Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog.
Controlled trial of ancrod and streptokinase in the treatment of deep vein thrombosis of lower limb.
Controlled trial of the sequential use of streptokinase and ancrod in the treatment of deep vein thrombosis of lower limb.
Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
Defibrinogenating enzymes.
Desmin 370, a low molecular weight dermatan sulfate, reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod.
Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod.
Effect of batroxobin on spontaneous echo contrast and hemorheology in left atrial appendage in atrial fibrillation assessed by transesophageal echocardiograpy.
Effect of drug administration on experimental renal glomerular thrombosis.
Effects of batroxobin treatment on the survival of random skin flaps in rats.
Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.
Failure of ancrod in the treatment of heparin-induced arterial thrombosis.
Further experience in the use of ancrod (Arvin) to prevent thrombosis on prosthetic heart valves.
Heparin, urokinase, and ancrod alter neutrophil function.
Heparin-associated thrombocytopenia and thrombosis: optimal therapy with ancrod.
Heparin-induced thrombosis treated with ancrod.
In vivo effect of a thrombin-like enzyme on platelet plug formation induced in mesenteric microvessels of mice.
Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries.
Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod.
New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon?
Normal activated clotting time despite adequate anticoagulation with ancrod in a patient with heparin-associated thrombocytopenia and thrombosis undergoing cardiopulmonary bypass.
Pharmacology and mechanism of action of ancrod: potential for inducing thrombosis.
Prevention of deep vein thrombosis by subcutaneous ancrod.
Preventive effects of batroxobin on experimental canine coronary thrombosis.
Prognosis of systemic lupus erythematosus and the factors that affect it.
Protein C activator from the venom of Agkistrodon blomhoffi ussuriensis retards thrombus formation in the arterio-venous shunt in rats.
Sensitivity of experimental venous and arterial thrombosis and bleeding to ancrod-induced defibrinogenation.
Subcutaneous ancrod in prevention of deep vein thrombosis after hip replacement surgery.
The effect of batroxobin on cochlear blood flow.
The protein C activator AB002 rapidly interrupts thrombus development in baboons.
The use of ancrod to prevent thrombosis on prosthetic heart valves. An experimental study.
Thrombosis in sickle-cell pain crises? Controlled trial of ancrod (Arvin) in young adults.
Treatment of central retinal vein thrombosis with ancrod.
Treatment of thrombosis by sequential therapy with ancrod followed by streptokinase. Clinical pharmacology and rheology.
Use of ancrod in acute or progressing ischemic cerebral infarction.
[An idiopathic floating left-ventricular thrombus]
[Blood coagulation inhibitors and thrombosis]
[Reptilase-induced molecular defect: treatment of thrombosis with Reptilase]
[The antithrombotic action of a protein C activator from the venom of Agkistrodon blomhoffi ussuriensis in thrombus formation in an extracorporeal shunt in rats]
Thyroid Cancer, Papillary
Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
Thyroid Neoplasms
Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Thyroid Nodule
Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Tuberculosis, Meningeal
Elevated Matrix Metalloproteinase Concentrations Offer Novel Insight Into Their Role in Pediatric Tuberculous Meningitis.
Uremia
Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Urinary Bladder Neoplasms
The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells.
Urinary Tract Infections
Urinary matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 biomarkers for predicting renal scar in children with urinary tract infection.
Uterine Inertia
[Morphological features of the myometrium in connective tissue dysplasia in women with uterine inertia].
Uveitis
Precision Medicine: Personalized Proteomics for the Diagnosis and Treatment of Idiopathic Inflammatory Disease.
Vascular System Injuries
Sensitivity of experimental venous and arterial thrombosis and bleeding to ancrod-induced defibrinogenation.
Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice.
Vascular Imaging of Matrix Metalloproteinase Activity as an Informative Preclinical Biomarker of Drug-induced Vascular Injury.
Vasculitis
Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Venous Thromboembolism
Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia.
Venous Thrombosis
Ancrod as prophylaxis or treatment for thromboembolism in patients with multiple trauma.
Ancrod-formed fibrin stimulates prostacyclin production of human umbilical vein endothelial cells via de novo synthesis of cyclooxygenase.
Batroxobin in combination with anticoagulation may promote venous sinus recanalization in cerebral venous thrombosis: A real-world experience.
Batroxobin Mobilizes Circulating Endothelial Progenitor Cells in Patients With Deep Vein Thrombosis.
Blood rheology in general medicine and surgery.
Controlled trial of ancrod and heparin in treatment of deep-vein thrombosis of lower limb.
Controlled trial of ancrod and streptokinase in the treatment of deep vein thrombosis of lower limb.
Controlled trial of the sequential use of streptokinase and ancrod in the treatment of deep vein thrombosis of lower limb.
Defibrinogenating enzymes.
In vivo effect of a thrombin-like enzyme on platelet plug formation induced in mesenteric microvessels of mice.
Prevention of deep vein thrombosis by subcutaneous ancrod.
Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia.
Subcutaneous ancrod in prevention of deep vein thrombosis after hip replacement surgery.
Subcutaneous ancrod in prevention of deep-vein thrombosis after operation for fractured neck of femur.
Subcutaneous ancrod in prevention of deep-vein thrombosis.
The effect of ancrod on perfusion of myocutaneous flaps.
Treatment of experimental venous thrombosis with streptokinase and ancrod (Arvin).
Use of ancrod in acute or progressing ischemic cerebral infarction.
[Thrombolytic agents]
Ventricular Dysfunction
Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure.
Ventricular Fibrillation
Ancrod decreases the frequency of cyclic flow variations and causes thrombolysis following acute coronary thrombosis.
Imbalance between tissue inhibitor of metalloproteinase 1 and matrix metalloproteinase 9 after cardiopulmonary resuscitation.
Vesico-Ureteral Reflux
Matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in vesicoureteral reflux.